Skip to main content
. 2015 Sep 16;35(37):12833–12844. doi: 10.1523/JNEUROSCI.0109-15.2015

Figure 12.

Figure 12.

Rapamycin treatment ± TFEB siRNA in DAergic cells expressing WT versus Q311X parkin. A, Representative Western blot and quantitation of cellular extracts isolated from N27 cells transfected with TFEB siRNA versus scrambled (Scr) siRNA probed with antibody against TFEB (actin used as loading control). Expressed as % Scr control. ***p < 0.001 versus Scr. B, Relative TFEB expression levels as assessed by RT-PCR from mRNA extracted from WT versus Q311X-transfected cells ± rapamycin (Rapa) treatment ± TFEB siRNA versus Scr siRNA control. ***p < 0.001 versus WT+Scr. **p < 0.01 versus WT+Scr. ++p < 0.01 versus Mut+Scr. #p < 0.05 WT+Scr+Rapa. −p < 0.05 versus Mut+Scr+Rapa. n = 3. C, Mitochondrial activity as monitored by TMRM fluorescence expressed as % WT+Scr siRNA control. ***p < 0.001 versus WT+Scr siRNA. +p < 0.05 versus Mut+Scr siRNA. #p < 0.05WT+Scr+Rapa. −p < 0.05 versus Mut+Scr+RAPA. n = 3 per condition. D, Measurement of cellular viability via MTT assay expressed as % WT+Scr siRNA control. ***p < 0.001 versus WT+Scr siRNA. +++p < 0.001 versus Mut+Scr siRNA. #p < 0.05 WT+Scr+Rapa. −p < 0.05 versus Mut+Scr+Rapa. n = 3 per condition. E, Relative PGC1α expression levels as assessed by RT-PCR from mRNA extracted from WT versus Q311X-transfected cells transfected with either TFEB siRNA or Scr siRNA control. ***p < 0.001 versus WT+Scr. ++p < 0.01 versus Mut+Scr. n = 3.